Abacus Bioscience Inc. is a Seattle-based biotechnology company developing *first‑in‑class active immunotherapies* that use a CD180‑based platform to overcome immune tolerance for treatments in oncology and chronic infectious disease, and it is advancing a humanized anti‑CD180 agonist (ABB071) and vaccine candidates such as an HBV core antigen therapeutic vaccine; the company is early‑stage with seed financing (roughly $4.4–4.5M) and a small team.[5][4][2]
High‑Level Overview
- Concise summary: Abacus Bioscience builds therapeutics that *actively* stimulate the immune system via CD180 agonism to elicit stronger anti‑tumor and antiviral responses than current tolerant states; its pipeline includes ABB071 (an anti‑CD180 agonistic antibody) and vaccine programs such as an HBV core antigen therapeutic vaccine.[5][4][2]
- What product it builds: Development candidates include a humanized anti‑CD180 agonistic antibody (ABB071) and therapeutic vaccine constructs aimed at overcoming immune tolerance in cancer and chronic infections.[4][2]
- Who it serves: Patients with cancers and chronic viral infections (e.g., hepatitis B) and potential partnering pharmaceutical companies seeking manufacturable immunotherapy assets.[2][4]
- What problem it solves: Targets immune tolerance — a central barrier in effective anti‑tumor and anti‑chronic infection immunity — by delivering CD180‑backbone immunogens or agonistic antibodies to reawaken durable immune responses.[1][2]
- Growth momentum: The company is preclinical/seed‑stage with published patent activity (including a granted patent for an HBV therapeutic vaccine) and has publicly listed early funding (~$4.4–4.52M); it has begun partnering/partnering‑interest outreach (e.g., BIO convention listing) but remains small and early in clinical development.[2][1][4]
Origin Story
- Founding and team: Sources indicate Abacus was formed from University of Washington–linked science and lists leaders including Alan Wahl (CEO) and Che‑Leung Law (CSO) among its early executives; one source says it was established in 2015 while others list founding as 2018 (the firm has used the prior name Shilshole Bioscience in records).[1][2]
- How the idea emerged: The company’s approach grew from academic/industry immunology work focused on CD180 (a B‑cell surface receptor) and the concept of using CD180‑based constructs or agonists to break immune tolerance to tumor antigens and chronic viral antigens.[1][5]
- Early traction / pivotal moments: Seed financing of roughly $4.4M supported preclinical work; the company has filed multiple patents (including a granted patent for an HBV core antigen therapeutic vaccine) and is marketing ABB071 for partnership opportunities, signaling translational progress toward IND‑enabling development.[2][1][4]
Core Differentiators
- CD180‑centric mechanism: A focused platform that uses CD180 agonism to actively prime B‑ and T‑cell responses rather than passively relying on checkpoint modulation.[1][5]
- Pipeline assets targeted for manufacturability: ABB071 is described as *highly manufacturable* with strong in vivo potency, an attractive combination for partners and developers.[4]
- Dual‑indication strategy: Technology designed for both oncology and chronic infectious disease (notably HBV), widening potential clinical and commercial pathways.[2][1]
- Early IP estate and grant activity: Multiple patent filings and at least one granted patent for an HBV therapeutic vaccine indicate protected innovations around their vaccine and immunotherapy designs.[2]
Role in the Broader Tech/biotech Landscape
- Trend alignment: Abacus rides two major trends—next‑generation active immunotherapies (moving beyond checkpoint inhibitors and passive biologics) and therapeutic vaccines for chronic infections—both high‑priority areas in biotech R&D.[5][2]
- Why timing matters: There is growing industry focus on overcoming immune tolerance to expand responder populations and to target chronic viral reservoirs; advances in antibody engineering and vaccine delivery improve the feasibility of CD180‑based approaches now versus a decade ago.[5][2]
- Market forces in its favor: Continued investment interest in immuno‑oncology, unmet need in therapeutic HBV treatments, and pharma appetite for partnerable biologics increase the company’s strategic options.[4][2]
- Ecosystem influence: If successful, a CD180 agonist or vaccine platform could provide a complementary modality to existing immunotherapies and attract collaboration from larger biopharma seeking novel immune‑priming mechanisms.[5][4]
Quick Take & Future Outlook
- What’s next: Near‑term milestones likely include continued preclinical optimization, IND‑enabling studies for ABB071 or vaccine candidates, potential first‑in‑human trials, and business development to secure partnerships or additional financing.[4][2]
- Trends that will shape them: Progress in translational immunology, competitive results from other immune‑priming platforms, regulatory expectations for therapeutic vaccines, and partner interest in manufacturable biologics will determine pace and valuation.[5][2]
- How their influence might evolve: Success in demonstrating that CD180‑based active immunotherapies deliver clinical benefit could position Abacus as a specialist provider of immune‑priming assets for oncology and chronic infection programs, but as an early, small company it will likely need partners or follow‑on capital to scale trials and commercialization.[4][2]
Notes and uncertainties
- Founding year discrepancy: public databases differ (2015 vs. 2018) and the company has previously used the name Shilshole Bioscience; these inconsistencies appear across sources and may reflect corporate formation versus rebranding dates.[1][2]
- Stage & public data: Abacus is seed/early stage with limited public financial disclosures; assertions about timelines and outcomes are contingent on preclinical success and future funding/partnerships.[2][3]
Sources: Abacus Bioscience’s corporate site and company profile page[5]; CB Insights company dossier with funding, patent and founding details[2]; Sahsen portfolio summary with founder names and early funding[1]; BIO/BIO Convention exhibitor listing describing ABB071 and partner interest[4]; company overview listings summarizing focus and size[3].
